Page last updated: 2024-12-05

4-fluorobenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

4-Fluorobenzoic acid is an organic compound with the formula C7H5FO2. It is a white solid that is soluble in water and organic solvents. 4-Fluorobenzoic acid is an important intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as a building block in the synthesis of polymers and other materials. 4-Fluorobenzoic acid is a relatively weak acid, with a pKa of 3.9. It is a relatively stable compound and is not easily oxidized or reduced. 4-Fluorobenzoic acid is an important intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as a building block in the synthesis of polymers and other materials. 4-Fluorobenzoic acid is a relatively weak acid, with a pKa of 3.9. It is a relatively stable compound and is not easily oxidized or reduced. 4-Fluorobenzoic acid has been studied for its potential use in the treatment of various diseases, including cancer and diabetes. It has also been shown to have antibacterial and antifungal activity. The compound is also used in the synthesis of a variety of other fluorinated compounds, including pharmaceuticals and agrochemicals.'

Cross-References

ID SourceID
PubMed CID9973
CHEMBL ID316860
CHEBI ID20364
SCHEMBL ID27498
MeSH IDM0079535

Synonyms (51)

Synonym
para-fluorobenzoic acid
CHEBI:20364 ,
CHEMBL316860
4-fluoro-benzoic acid
BB 0221130
inchi=1/c7h5fo2/c8-6-3-1-5(2-4-6)7(9)10/h1-4h,(h,9,10
benzoic acid, 4-fluoro-
nsc-10321
nsc10321
benzoic acid, p-fluoro-
p-fluorobenzoic acid
456-22-4
4-fluorobenzoic acid ,
C02371
4-fluorobenzoic acid, 99%, purified by sublimation
4-fluorobenzoic acid, 98%
BMSE000739
FT-0650144
F0112
AKOS000118941
A826862
p-fluoro-benzoic acid
AE-562/40177766
STL141031
v5roo2hou4 ,
unii-v5roo2hou4
einecs 207-259-0
nsc 10321
4-fluorobenzoicacid
AM20040510
4-fluorobenzoic acid [mi]
fluorobenzoic acid, p-
SCHEMBL27498
Z57367354
DTXSID9060023
p-flurobenzoic acid
4-flouro benzoic acid
4-fluoro benzoic acid
AC-10259
Q-200470
1y6 ,
PS-9056
mfcd00002530
F2191-0062
D70922
CS-W014393
Q63390495
4-fluorobenzoic acid,purified by sublimation
SY001592
4-flurobenzoic acid
EN300-18213

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"9% (mean+/-SE, n=6) of dosage after 48h of administration."( Identification and simultaneous determination of p-FHA and p-FBA, two metabolites of anti-tumor agent--Fluorapacin in rat urine.
An, H; Jiang, H; Pan, H; Xu, X; Zeng, S; Zhou, H, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial xenobiotic metaboliteAny bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
fluorobenzoic acidAny benzoic acid carrying at least one fluoro substituent on the benzene ring. Fluorobenzoic acids are important intermediates in the synthesis of antibacterial drugs.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1605095Inhibition of N-terminal His6-sumo-tagged full length Staphylococcus aureus ClpP expressed in Escherichia coli BL2 (DE3) at 10 uM pre-incubated for 10 mins before Suc-LY-AMC addition and measured after 1 hr by fluorescence based assay relative to control2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
AID1214935Drug level in Sprague-Dawley rat RBC treated with BFBDS by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID1214941Drug level in Sprague-Dawley rat whole blood treated with BFBTS by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID342464Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID226477Hammett constant was determined1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID1214934Drug level in Sprague-Dawley rat RBC treated with BFBTS by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID1214931Drug metabolism in Sprague-Dawley rat RBC assessed as p-FBM metabolite formation by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID226478Hammett constant was evaluated1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID1214948Drug level in Sprague-Dawley rat whole blood treated with BFBTS at 50 uM by UPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID1214933Drug metabolism in Sprague-Dawley rat RBC assessed as BFBTS formation by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID1235354Antifungal activity against Cochliobolus lunatus strain MUCL 38696 at 100 uM by growth based assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Benzoic acid derivatives with improved antifungal activity: Design, synthesis, structure-activity relationship (SAR) and CYP53 docking studies.
AID28731Partition coefficient (logD2.0)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1214936Drug level in Sprague-Dawley rat RBC treated with p-FBM by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID28497log (1/C') was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1214966Retention time in Sprague-Dawley rat whole blood treated with 50 uM Bis(4-fluorobenzyl)trisulfide after 15 mins by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID28691log LD50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1214930Drug metabolism in Sprague-Dawley rat RBC assessed as BFBDS metabolite formation by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
AID1214967Drug level in Sprague-Dawley rat whole blood treated with BFBTS at 50 uM after 15 mins by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Metabolism of bis(4-fluorobenzyl)trisulfide and its formation of hemoglobin adduct in rat erythrocytes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (8.70)18.7374
1990's10 (21.74)18.2507
2000's14 (30.43)29.6817
2010's16 (34.78)24.3611
2020's2 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.45 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index50.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other46 (97.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]